The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer.
Abstract
PURPOSE: Breast cancer frequently overexpresses the product of the HER2 proto-oncogene, a 185-kd growth factor receptor (p185HER2). The recombinant humanized monoclonal antibody (rhuMAb) HER2 has high affinity for p185HER2 and inhibits the growth of breast cancer cells that overexpress HER2. We evaluated the efficacy and toxicity of weekly intravenous administration of rhuMAb HER2 in patients with HER2-overexpressing metastatic breast cancer. PATIENTS AND METHODS: We treated 46 patients with metastatic breast carcinomas that overexpressed HER2. Patients received a loading dose of 250 mg of intravenous rhuMAb HER2, then 10 weekly doses of 100 mg each. Patients with no disease progression at the completion of this treatment period were offered a maintenance phase of 100 mg/wk. RESULTS: Study patients had extensive metastatic disease, and most had received extensive prior anticancer therapy. Adequate pharmacokinetic levels of rhuMAb HER2 were obtained in 90% of the patients. Toxicity was minimal and no antibodies against rhuMAb HER2 were detected in any patients. Objective responses were seen in five of 43 assessable patients, and included one complete remission and four partial remissions (overall response rate, 11.6%; 95% confidence interval, 4.36 to 25.9). Responses were observed in liver, mediastinum, lymph nodes, and chest wall lesions. Minor responses, seen in two patients, and stable disease, which occurred in 14 patients, lasted for a median of 5.1 months. CONCLUSION: rhuMAb HER2 is well tolerated and clinically active in patients with HER2-overexpressing metastatic breast cancers that had received extensive prior therapy. This is evidence that targeting growth factor receptors can cause regression of human cancer and justifies further evaluation of this agent.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Statistical Methods for Rates and Proportions
Fleiss, J. L., Levin, B., & Paik, M. C. (2003) · Wiley Series in Probability and Statistics · doi:10.1002/0471445428 · Cited by 18,646
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760
Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian Cancer
Slamon, D. J., Godolphin, W., Jones, L. A., Holt, J. A., Wong, S. G., Keith, D. E., Levin, W. J., Stuart, S. G., Udove, J., Ullrich, A., et al. (1989) · Science · doi:10.1126/science.2470152 · Cited by 6,816
Aaronson, S. A. (1991) · Science · doi:10.1126/science.1659742 · Cited by 2,028
Humanization of an anti-p185HER2 antibody for human cancer therapy.
Carter, P., Presta, L., Gorman, C. M., Ridgway, J. B., Henner, D., Wong, W. L., Rowland, A. M., Kotts, C., Carver, M. E., & Shepard, H. M. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.10.4285 · Cited by 1,918
Coussens, L., Yang-Feng, T. L., Liao, Y.-C., Chen, E., Gray, A., McGrath, J., Seeburg, P. H., Libermann, T. A., Schlessinger, J., Francke, U., et al. (1985) · Science · doi:10.1126/science.2999974 · Cited by 1,814
Guy, C. T., Webster, M. A., Schaller, M., Parsons, T. J., Cardiff, R. D., & Muller, W. J. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.22.10578 · Cited by 1,193
erb B-2 Is a Potent Oncogene When Overexpressed in NIH/3T3 Cells
Di Fiore, P. P., Pierce, J. H., Kraus, M. H., Segatto, O., King, C. R., & Aaronson, S. A. (1987) · Science · doi:10.1126/science.2885917 · Cited by 1,010
The biology of erbB-2/nue/HER-2 and its role in cancer
Hynes, N. (1994) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/0304-419x(94)90012-4 · Cited by 971
Neu-Protein Overexpression in Breast Cancer
van de Vijver, M. J., Peterse, J. L., Mooi, W. J., Wisman, P., Lomans, J., Dalesio, O., & Nusse, R. (1988) · New England Journal of Medicine · doi:10.1056/nejm198811103191902 · Cited by 860
Cited by
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
“analyzed (%) «1 48/143 (34) 49/136 (36) 31/91 (34) 27/95 (28) 2 38/143 (27) 48/136 (35) 32/91 (35) 35/95 (37) »3 57/143 (40) 39/136 (29) 28/91 (31) 33/95 (35)”
Self-citationUntangling the ErbB signalling network
Yarden, Y., & Sliwkowski, M. X. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35052073 · Cited by 6,974
“(Abl, a proto-oncogenic tyrosine kinase whose targets are poorly understood; Akt, a serine/threonine kinase that phosphorylates the anti-apoptotic protein Bad and the ribosomal S6 kinase (S6K); GAP, GTPase activating protein; HB-EGF, heparin-binding EGF; Jak, janus kinase; PKC, protein kinase C; PLCγ, phospholipase Cγ…”
InfluentialTrastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer
Piccart-Gebhart, M. J., Procter, M., Leyland-Jones, B., Goldhirsch, A., Untch, M., Smith, I., Gianni, L., Baselga, J., Bell, R., Jackisch, C., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa052306 · Cited by 5,084
Self-citationCobleigh, M. A., Vogel, C. L., Tripathy, D., Robert, N. J., Scholl, S., Fehrenbacher, L., Wolter, J. M., Paton, V., Shak, S., Lieberman, G., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.9.2639 · Cited by 2,765
Self-citationTrastuzumab — Mechanism of Action and Use in Clinical Practice
Hudis, C. A. (2007) · New England Journal of Medicine · doi:10.1056/nejmra043186 · Cited by 2,585
Self-citationOlayioye, M. A. (2000) · The EMBO Journal · doi:10.1093/emboj/19.13.3159 · Cited by 2,434
Harris, L., Fritsche, H., Mennel, R., Norton, L., Ravdin, P., Taube, S., Somerfield, M. R., Hayes, D. F., & Bast, R. C. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.2364 · Cited by 2,217
Self-citationThe EGF receptor family as targets for cancer therapy
Mendelsohn, J., & Baselga, J. (2000) · Oncogene · doi:10.1038/sj.onc.1204082 · Cited by 1,340
Self-citationBendell, J. C., Domchek, S. M., Burstein, H. J., Harris, L., Younger, J., Kuter, I., Bunnell, C., Rue, M., Gelman, R., & Winer, E. (2003) · Cancer · doi:10.1002/cncr.11436 · Cited by 1,320
Monoclonal antibody therapy of cancer
Adams, G. P., & Weiner, L. M. (2005) · Nature Biotechnology · doi:10.1038/nbt1137 · Cited by 1,246
Buzdar, A. U., Ibrahim, N. K., Francis, D., Booser, D. J., Thomas, E. S., Theriault, R. L., Pusztai, L., Green, M. C., Arun, B. K., Giordano, S. H., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.07.032 · Cited by 1,171
Novel anticancer targets: revisiting ERBB2 and discovering ERBB3
Baselga, J., & Swain, S. M. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2656 · Cited by 1,142
Self-citationPegram, M. D., Lipton, A., Hayes, D. F., Weber, B. L., Baselga, J. M., Tripathy, D., Baly, D., Baughman, S. A., Twaddell, T., Glaspy, J. A., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.8.2659 · Cited by 1,067
Self-citationOvarian Surface Epithelium: Biology, Endocrinology, and Pathology*
Auersperg, N., Wong, A. S. T., Choi, K.-C., Kang, S. K., & Leung, P. C. K. (2001) · Endocrine Reviews · doi:10.1210/edrv.22.2.0422 · Cited by 1,046
The ERBB network: at last, cancer therapy meets systems biology
Yarden, Y., & Pines, G. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3309 · Cited by 988
Ross, J. S., & Fletcher, J. A. (1998) · STEM CELLS · doi:10.1002/stem.160413 · Cited by 985
Mechanisms of Disease: understanding resistance to HER2-targeted therapy in human breast cancer
Nahta, R., Yu, D., Hung, M.-C., Hortobagyi, G. N., & Esteva, F. J. (2006) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0509 · Cited by 916
Evolution of Cancer Pharmacological Treatments at the Turn of the Third Millennium
Falzone, L., Salomone, S., & Libra, M. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01300 · Cited by 908
Scaltriti, M., Rojo, F., Ocana, A., Anido, J., Guzman, M., Cortes, J., Di Cosimo, S., Matias-Guiu, X., Ramon y Cajal, S., Arribas, J., et al. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djk134 · Cited by 895
Self-citationInsulin-Like Growth Factor-I Receptor Signaling and Resistance to Trastuzumab (Herceptin)
Lu, Y., Zi, X., Zhao, Y., Mascarenhas, D., & Pollak, M. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.24.1852 · Cited by 882
Bast, R. C., Ravdin, P., Hayes, D. F., Bates, S., Fritsche, H., Jessup, J. M., Kemeny, N., Locker, G. Y., Mennel, R. G., & Somerfield, M. R. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.6.1865 · Cited by 879
Improving the efficacy of antibody-based cancer therapies
Carter, P. (2001) · Nature Reviews Cancer · doi:10.1038/35101072 · Cited by 833
Nahta, R., Yuan, L. X. H., Zhang, B., Kobayashi, R., & Esteva, F. J. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3841 · Cited by 793
Hortobagyi, G. N. (1998) · New England Journal of Medicine · doi:10.1056/nejm199810013391407 · Cited by 781
HER kinase inhibition in patients with HER2- and HER3-mutant cancers
Hyman, D. M., Piha-Paul, S. A., Won, H., Rodon, J., Saura, C., Shapiro, G. I., Juric, D., Quinn, D. I., Moreno, V., Doger, B., et al. (2018) · Nature · doi:10.1038/nature25475 · Cited by 780
Self-citationAdjuvant Paclitaxel and Trastuzumab for Node-Negative, HER2-Positive Breast Cancer
Tolaney, S. M., Barry, W. T., Dang, C. T., Yardley, D. A., Moy, B., Marcom, P. K., Albain, K. S., Rugo, H. S., Ellis, M., Shapira, I., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1406281 · Cited by 753
Self-citationThe transcriptional repressor Snail promotes mammary tumor recurrence
Moody, S. E., Perez, D., Pan, T.-C., Sarkisian, C. J., Portocarrero, C. P., Sterner, C. J., Notorfrancesco, K. L., Cardiff, R. D., & Chodosh, L. A. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.07.009 · Cited by 750
Baselga, J., Pfister, D., Cooper, M. R., Cohen, R., Burtness, B., Bos, M., D’Andrea, G., Seidman, A., Norton, L., Gunnett, K., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.4.904 · Cited by 741
Self-citationPegram, M., Hsu, S., Lewis, G., Pietras, R., Beryt, M., Sliwkowski, M., Coombs, D., Baly, D., Kabbinavar, F., & Slamon, D. (1999) · Oncogene · doi:10.1038/sj.onc.1202526 · Cited by 692
Prenzel, N., Fischer, O. M., Streit, S., Hart, S., & Ullrich, A. (2001) · Endocrine-related cancer · doi:10.1677/erc.0.0080011 · Cited by 673
STAT proteins: novel molecular targets for cancer drug discovery
Turkson, J., & Jove, R. (2000) · Oncogene · doi:10.1038/sj.onc.1204086 · Cited by 643
Prognostic and Predictive Factors in Early-Stage Breast Cancer
Cianfrocca, M., & Goldstein, L. J. (2004) · The Oncologist · doi:10.1634/theoncologist.9-6-606 · Cited by 637
Molecular mechanisms underlying ErbB2/HER2 action in breast cancer
Harari, D., & Yarden, Y. (2000) · Oncogene · doi:10.1038/sj.onc.1203973 · Cited by 633
Nanocarriers for cancer-targeted drug delivery
Kumari, P., Ghosh, B., & Biswas, S. (2016) · Journal of Drug Targeting · doi:10.3109/1061186x.2015.1051049 · Cited by 607
Trastuzumab containing regimens for early breast cancer
Moja, L., Tagliabue, L., Balduzzi, S., Parmelli, E., Pistotti, V., Guarneri, V., & D'Amico, R. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006243.pub2 · Cited by 604
Bookman, M. A., Darcy, K. M., Clarke-Pearson, D., Boothby, R. A., & Horowitz, I. R. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.10.104 · Cited by 598
Esteva, F. J., Valero, V., Booser, D., Guerra, L. T., Murray, J. L., Pusztai, L., Cristofanilli, M., Arun, B., Esmaeli, B., Fritsche, H. A., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.07.058 · Cited by 566
Seidman, A. D., Fornier, M. N., Esteva, F. J., Tan, L., Kaptain, S., Bach, A., Panageas, K. S., Arroyo, C., Valero, V., Currie, V., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.10.2587 · Cited by 547
Self-citationBiochemical and Clinical Implications of the ErbB/HER Signaling Network of Growth Factor Receptors
(1999) · Advances in Cancer Research · doi:10.1016/s0065-230x(08)60784-8 · Cited by 540
Nagy, P., Friedländer, E., Tanner, M., Kapanen, A. I., Carraway, K. L., Isola, J., & Jovin, T. M. (2005) · Cancer Research · doi:10.1158/0008-5472.473.65.2 · Cited by 523
Riethmüller, G., Holz, E., Schlimok, G., Schmiegel, W., Raab, R., Höffken, K., Gruber, R., Funke, I., Pichlmaier, H., Hirche, H., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.5.1788 · Cited by 517
An efficient route to human bispecific IgG
Merchant, A. M., Zhu, Z., Yuan, J. Q., Goddard, A., Adams, C. W., Presta, L. G., & Carter, P. (1998) · Nature Biotechnology · doi:10.1038/nbt0798-677 · Cited by 510
Resistance to Trastuzumab in Breast Cancer
Pohlmann, P. R., Mayer, I. A., & Mernaugh, R. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0636 · Cited by 505
Eichhorn, P. J. A., Gili, M., Scaltriti, M., Serra, V., Guzman, M., Nijkamp, W., Beijersbergen, R. L., Valero, V., Seoane, J., Bernards, R., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1740 · Cited by 499
Self-citationDetection and Clinical Importance of Micrometastatic Disease
Pantel, K., Cote, R. J., & Fodstad, O. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.13.1113 · Cited by 493
Neuregulins and Their Receptors: A Versatile Signaling Module in Organogenesis and Oncogenesis
Burden, S., & Yarden, Y. (1997) · Neuron · doi:10.1016/s0896-6273(00)80324-4 · Cited by 476
Multiple Roles for the Major Histocompatibility Complex Class I– Related Receptor FcRn
Ghetie, V., & Ward, E. S. (2000) · Annual Review of Immunology · doi:10.1146/annurev.immunol.18.1.739 · Cited by 474
Goldenberg, M. M. (1999) · Clinical Therapeutics · doi:10.1016/s0149-2918(00)88288-0 · Cited by 453
ERBB2 oncogene in human breast cancer and its clinical significance
Révillion, F., Bonneterre, J., & Peyrat, J. P. (1998) · European Journal of Cancer · doi:10.1016/s0959-8049(97)10157-5 · Cited by 448
Herceptin: mechanisms of action and resistance
Nahta, R., & Esteva, F. J. (2006) · Cancer Letters · doi:10.1016/j.canlet.2005.01.041 · Cited by 446
Herbst, R. S., & Shin, D. M. (2002) · Cancer · doi:10.1002/cncr.10372 · Cited by 446
Scaltriti, M., Verma, C., Guzman, M., Jimenez, J., Parra, J. L., Pedersen, K., Smith, D. J., Landolfi, S., Ramon y Cajal, S., Arribas, J., et al. (2009) · Oncogene · doi:10.1038/onc.2008.432 · Cited by 439
Self-citationHER2 therapy: Molecular mechanisms of trastuzumab resistance
Nahta, R., & Esteva, F. J. (2006) · Breast Cancer Research · doi:10.1186/bcr1612 · Cited by 433
Chaperone-dependent E3 ubiquitin ligase CHIP mediates a degradative pathway for c-ErbB2/Neu
Xu, W., Marcu, M., Yuan, X., Mimnaugh, E., Patterson, C., & Neckers, L. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.202365899 · Cited by 433
Juric, D., Rodon, J., Tabernero, J., Janku, F., Burris, H. A., Schellens, J. H. M., Middleton, M. R., Berlin, J., Schuler, M., Gil-Martin, M., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.72.7107 · Cited by 431
Self-citationOverexpression of ErbB2 in cancer and ErbB2-targeting strategies
Yu, D., & Hung, M.-C. (2000) · Oncogene · doi:10.1038/sj.onc.1203972 · Cited by 430
Baselga, J., Carbonell, X., Castañeda-Soto, N.-J., Clemens, M., Green, M., Harvey, V., Morales, S., Barton, C., & Ghahramani, P. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.014 · Cited by 425
Self-citationStemmler, H.-J., Schmitt, M., Willems, A., Bernhard, H., Harbeck, N., & Heinemann, V. (2007) · Anti-Cancer Drugs · doi:10.1097/01.cad.0000236313.50833.ee · Cited by 412
Phase II and Tumor Pharmacodynamic Study of Gefitinib in Patients with Advanced Breast Cancer
Baselga, J., Albanell, J., Ruiz, A., Lluch, A., Gascón, P., Guillém, V., González, S., Sauleda, S., Marimón, I., Tabernero, J. M., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.08.326 · Cited by 411
Self-citationBraun, S., Kentenich, C., Janni, W., Hepp, F., de Waal, J., Willgeroth, F., Sommer, H., & Pantel, K. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.1.80 · Cited by 394
Hurvitz, S. A., Dirix, L., Kocsis, J., Bianchi, G. V., Lu, J., Vinholes, J., Guardino, E., Song, C., Tong, B., Ng, V., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.9694 · Cited by 392
Receptor tyrosine kinase signalling as a target for cancer intervention strategies.
Zwick, E., Bange, J., & Ullrich, A. (2001) · Endocrine-related cancer · doi:10.1677/erc.0.0080161 · Cited by 384
Viani, G. A., Afonso, S. L., Stefano, E. J., De Fendi, L. I., & Soares, F. V. (2007) · BMC Cancer · doi:10.1186/1471-2407-7-153 · Cited by 381
Burstein, H. J., Kuter, I., Campos, S. M., Gelman, R. S., Tribou, L., Parker, L. M., Manola, J., Younger, J., Matulonis, U., Bunnell, C. A., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.10.2722 · Cited by 366
Therapeutic monoclonal antibodies
Breedveld, F. (2000) · The Lancet · doi:10.1016/s0140-6736(00)01034-5 · Cited by 359
Huang, F., Reeves, K., Han, X., Fairchild, C., Platero, S., Wong, T. W., Lee, F., Shaw, P., & Clark, E. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3633 · Cited by 344
Disis, M. L., Pupa, S. M., Gralow, J. R., Dittadi, R., Menard, S., & Cheever, M. A. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.11.3363 · Cited by 345
Moody, S. E., Sarkisian, C. J., Hahn, K. T., Gunther, E. J., Pickup, S., Dugan, K. D., Innocent, N., Cardiff, R. D., Schnall, M. D., & Chodosh, L. A. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00212-x · Cited by 345
Target-based agents against ErbB receptors and their ligands: a novel approach to cancer treatment.
Normanno, N., Bianco, C., De Luca, A., Maiello, M. R., & Salomon, D. S. (2003) · Endocrine-related cancer · doi:10.1677/erc.0.0100001 · Cited by 336
Tumor targeting using anti-her2 immunoliposomes
Park, J. W., Kirpotin, D. B., Hong, K., Shalaby, R., Shao, Y., Nielsen, U. B., Marks, J. D., Papahadjopoulos, D., & Benz, C. C. (2001) · Journal of Controlled Release · doi:10.1016/s0168-3659(01)00315-7 · Cited by 335
Self-citationTrastuzumab: triumphs and tribulations
Nahta, R., & Esteva, F. J. (2007) · Oncogene · doi:10.1038/sj.onc.1210379 · Cited by 334
Molecular mechanisms underlying endocytosis and sorting of ErbB receptor tyrosine kinases
Waterman, H., & Yarden, Y. (2001) · FEBS Letters · doi:10.1016/s0014-5793(01)02117-2 · Cited by 314
Expression of HER2/erb B-2 Correlates With Survival in Osteosarcoma
Gorlick, R., Huvos, A. G., Heller, G., Aledo, A., Beardsley, G. P., Healey, J. H., & Meyers, P. A. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.9.2781 · Cited by 303
Role of HER2 gene overexpression in breast carcinoma
M�nard, S., Tagliabue, E., Campiglio, M., & Pupa, S. M. (2000) · Journal of Cellular Physiology · doi:10.1002/(sici)1097-4652(200002)182:2<150::aid-jcp3>3.0.co;2-e · Cited by 303
Pestalozzi, B. C., & Brignoli, S. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.11.2349 · Cited by 301
Fleming, G. F., Sill, M. W., Darcy, K. M., McMeekin, D. S., Thigpen, J. T., Adler, L. M., Berek, J. S., Chapman, J. A., DiSilvestro, P. A., Horowitz, I. R., et al. (2010) · Gynecologic Oncology · doi:10.1016/j.ygyno.2009.09.025 · Cited by 300
P27kip1 Down-Regulation Is Associated with Trastuzumab Resistance in Breast Cancer Cells
Nahta, R., Takahashi, T., Ueno, N. T., Hung, M.-C., & Esteva, F. J. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3900 · Cited by 298
“Clinical studies established that trastuzumab is active against HER-2overexpressing metastatic breast cancers (3, 4), leading to its approval in 1998 by the United States Food and Drug Administration.”
BackgroundKeilholz, U., Weber, J., Finke, J. H., Gabrilovich, D. I., Kast, W. M., Disis, M. L., Kirkwood, J. M., Scheibenbogen, C., Schlom, J., Maino, V. C., et al. (2002) · Journal of Immunotherapy · doi:10.1097/00002371-200203000-00001 · Cited by 298
Lane, H. A., Beuvink, I., Motoyama, A. B., Daly, J. M., Neve, R. M., & Hynes, N. E. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.9.3210-3223.2000 · Cited by 298
Second-Line Treatment of Ovarian Cancer
Markman, M., & Bookman, M. A. (2000) · The Oncologist · doi:10.1634/theoncologist.5-1-26 · Cited by 296
Current Treatment of Osteosarcoma
Ferguson, W. S., & Goorin, A. M. (2001) · Cancer Investigation · doi:10.1081/cnv-100102557 · Cited by 295
Leyland-Jones, B., Gelmon, K., Ayoub, J.-P., Arnold, A., Verma, S., Dias, R., & Ghahramani, P. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.12.109 · Cited by 293
Nanopreparations for organelle-specific delivery in cancer
Biswas, S., & Torchilin, V. P. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.11.004 · Cited by 292
Yamauchi, H., Stearns, V., & Hayes, D. F. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.8.2334 · Cited by 291
Protein tyrosine kinases and cancer
Kolibaba, K. S., & Druker, B. J. (1997) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/s0304-419x(97)00022-x · Cited by 291
Trastuzumab: A Review of its Use in the Treatment of Metastatic Breast Cancer Overexpressing HER2
McKeage, K., & Perry, C. M. (2002) · Drugs · doi:10.2165/00003495-200262010-00008 · Cited by 289
Tumor-Derived Cell Lines as Molecular Models of Cancer Pharmacogenomics
Goodspeed, A., Heiser, L. M., Gray, J. W., & Costello, J. C. (2016) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-15-0189 · Cited by 276
Normanno, N., Campiglio, M., De Luca, A., Somenzi, G., Maiello, M., Ciardiello, F., Gianni, L., Salomon, D. S., & Menard, S. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf020 · Cited by 273
Nahta, R., Yuan, L. X. H., Du, Y., & Esteva, F. J. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0423 · Cited by 267
Basso, A. D., Solit, D. B., Munster, P. N., & Rosen, N. (2002) · Oncogene · doi:10.1038/sj.onc.1205184 · Cited by 265
Herceptin in patients with advanced or metastatic salivary gland carcinomas. A phase II study
Haddad, R., Colevas, A. D., Krane, J. F., Cooper, D., Glisson, B., Amrein, P. C., Weeks, L., Costello, R., & Posner, M. (2003) · Oral Oncology · doi:10.1016/s1368-8375(03)00097-6 · Cited by 264
Menendez, J. A., Vellon, L., Colomer, R., & Lupu, R. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi090 · Cited by 263
Ross, J. S., & Fletcher, J. A. (1998) · The Oncologist · doi:10.1634/theoncologist.3-4-237 · Cited by 260
Her-2/neu as a Predictive Marker of Response to Breast Cancer Therapy
Pegram, M. D., Pauletti, G., & Slamon, D. J. (1998) · Breast Cancer Research and Treatment · doi:10.1023/a:1006111117877 · Cited by 259
Fahrner, R. L., Knudsen, H. L., Basey, C. D., Galan, W., Feuerhelm, D., Vanderlaan, M., & Blank, G. S. (2001) · Biotechnology and Genetic Engineering Reviews · doi:10.1080/02648725.2001.10648017 · Cited by 259
Mechanism of action of trastuzumab and scientific update
BASELGA, J. (2001) · Seminars in Oncology · doi:10.1016/s0093-7754(01)90276-3 · Cited by 258
Self-citationOsborne, C., Wilson, P., & Tripathy, D. (2004) · The Oncologist · doi:10.1634/theoncologist.9-4-361 · Cited by 257
Self-citationLin, Y. S., Nguyen, C., Mendoza, J.-L., Escandon, E., Fei, D., Meng, Y. G., & Modi, N. B. (1999) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37962-5 · Cited by 255
Real-Time Reverse Transcription-PCR Assay for Future Management of ERBB2-based Clinical Applications
Bièche, I., Onody, P., Laurendeau, I., Olivi, M., Vidaud, D., Lidereau, R., & Vidaud, M. (1999) · Clinical Chemistry · doi:10.1093/clinchem/45.8.1148 · Cited by 254
Epidermal growth factor receptor: a promising target in solid tumours
Laskin, J. J., & Sandler, A. B. (2004) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2003.10.002 · Cited by 253
Metadata
- Authors
- Baselga, J., Tripathy, D., Mendelsohn, J., Baughman, S., Benz, C. C., Dantis, L., Sklarin, N. T., Seidman, A. D., Hudis, C. A., Moore, J., Rosen, P. P., Twaddell, T., Henderson, I. C., & Norton, L.
- Venue
- Journal of Clinical Oncology
- Published
- 1996-03
- Volume
- 14
- Issue
- 3
- Pages
- 737-744
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2222638000
- Cited by
- 1,380
- References
- 28
- FWCI
- 26.17
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.